Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free NBIX Stock Alerts

Neurocrine Biosciences (NBIX) Competitors

Neurocrine Biosciences logo
$150.82 -5.67 (-3.62%)
Closing price 08/13/2026 04:00 PM Eastern
Extended Trading
$150.66 -0.16 (-0.11%)
As of 08:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

NBIX vs. TAK, TEVA, ONC, RPRX, and ZTS

Should you buy Neurocrine Biosciences stock or one of its competitors? Neurocrine Biosciences's main competitors and comparable companies include Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Royalty Pharma (RPRX), and Zoetis (ZTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Neurocrine Biosciences compare to Takeda Pharmaceutical?

Neurocrine Biosciences (NASDAQ:NBIX) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Neurocrine Biosciences has higher earnings, but lower revenue than Takeda Pharmaceutical. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurocrine Biosciences$2.86B5.36$478.60M$6.8222.11
Takeda Pharmaceutical$28.32B1.97-$1.01B$0.3451.19

Neurocrine Biosciences currently has a consensus price target of $200.86, suggesting a potential upside of 33.18%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Neurocrine Biosciences is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neurocrine Biosciences
0 Sell rating(s)
4 Hold rating(s)
19 Buy rating(s)
1 Strong Buy rating(s)
2.88
Takeda Pharmaceutical
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, Takeda Pharmaceutical had 6 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 26 mentions for Takeda Pharmaceutical and 20 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.62 beat Takeda Pharmaceutical's score of 0.15 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neurocrine Biosciences
8 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Positive
Takeda Pharmaceutical
14 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Neurocrine Biosciences has a net margin of 20.91% compared to Takeda Pharmaceutical's net margin of 3.80%. Neurocrine Biosciences' return on equity of 22.43% beat Takeda Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Neurocrine Biosciences20.91% 22.43% 15.64%
Takeda Pharmaceutical 3.80%10.95%5.34%

Neurocrine Biosciences has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.08, meaning that its stock price is 108% less volatile than the broader market.

Summary

Neurocrine Biosciences beats Takeda Pharmaceutical on 14 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Teva Pharmaceutical Industries?

Neurocrine Biosciences (NASDAQ:NBIX) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

In the previous week, Neurocrine Biosciences and Neurocrine Biosciences both had 20 articles in the media. Teva Pharmaceutical Industries' average media sentiment score of 0.90 beat Neurocrine Biosciences' score of 0.62 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neurocrine Biosciences
8 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Positive
Teva Pharmaceutical Industries
7 Very Positive mention(s)
8 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Neurocrine Biosciences presently has a consensus target price of $200.86, indicating a potential upside of 33.18%. Teva Pharmaceutical Industries has a consensus target price of $42.22, indicating a potential upside of 15.62%. Given Neurocrine Biosciences' higher probable upside, research analysts clearly believe Neurocrine Biosciences is more favorable than Teva Pharmaceutical Industries.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neurocrine Biosciences
0 Sell rating(s)
4 Hold rating(s)
19 Buy rating(s)
1 Strong Buy rating(s)
2.88
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

Neurocrine Biosciences has a net margin of 20.91% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Neurocrine Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Neurocrine Biosciences20.91% 22.43% 15.64%
Teva Pharmaceutical Industries 4.08%32.64%6.34%

Teva Pharmaceutical Industries has higher revenue and earnings than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurocrine Biosciences$2.86B5.36$478.60M$6.8222.11
Teva Pharmaceutical Industries$17.31B2.46$1.41B$0.6060.86

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Neurocrine Biosciences has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

Summary

Neurocrine Biosciences beats Teva Pharmaceutical Industries on 9 of the 16 factors compared between the two stocks.

How does Neurocrine Biosciences compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, BeOne Medicines had 12 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 32 mentions for BeOne Medicines and 20 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.62 beat BeOne Medicines' score of 0.44 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BeOne Medicines
11 Very Positive mention(s)
4 Positive mention(s)
11 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Neurocrine Biosciences
8 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Positive

BeOne Medicines presently has a consensus price target of $402.14, suggesting a potential upside of 12.96%. Neurocrine Biosciences has a consensus price target of $200.86, suggesting a potential upside of 33.18%. Given Neurocrine Biosciences' higher probable upside, analysts plainly believe Neurocrine Biosciences is more favorable than BeOne Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BeOne Medicines
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
3 Strong Buy rating(s)
3.00
Neurocrine Biosciences
0 Sell rating(s)
4 Hold rating(s)
19 Buy rating(s)
1 Strong Buy rating(s)
2.88

BeOne Medicines has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

Neurocrine Biosciences has a net margin of 20.91% compared to BeOne Medicines' net margin of 10.70%. Neurocrine Biosciences' return on equity of 22.43% beat BeOne Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
BeOne Medicines10.70% 14.23% 7.82%
Neurocrine Biosciences 20.91%22.43%15.64%

Neurocrine Biosciences has lower revenue, but higher earnings than BeOne Medicines. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeOne Medicines$5.34B7.31$286.93M$5.6862.68
Neurocrine Biosciences$2.86B5.36$478.60M$6.8222.11

Summary

Neurocrine Biosciences beats BeOne Medicines on 9 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

Royalty Pharma has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Royalty Pharma has a net margin of 32.14% compared to Neurocrine Biosciences' net margin of 20.91%. Royalty Pharma's return on equity of 30.01% beat Neurocrine Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Royalty Pharma32.14% 30.01% 14.91%
Neurocrine Biosciences 20.91%22.43%15.64%

Royalty Pharma has higher earnings, but lower revenue than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty Pharma$2.38B14.18$770.95M$1.4540.39
Neurocrine Biosciences$2.86B5.36$478.60M$6.8222.11

Royalty Pharma currently has a consensus price target of $60.86, suggesting a potential upside of 3.92%. Neurocrine Biosciences has a consensus price target of $200.86, suggesting a potential upside of 33.18%. Given Neurocrine Biosciences' higher probable upside, analysts clearly believe Neurocrine Biosciences is more favorable than Royalty Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Royalty Pharma
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00
Neurocrine Biosciences
0 Sell rating(s)
4 Hold rating(s)
19 Buy rating(s)
1 Strong Buy rating(s)
2.88

In the previous week, Neurocrine Biosciences had 8 more articles in the media than Royalty Pharma. MarketBeat recorded 20 mentions for Neurocrine Biosciences and 12 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.90 beat Neurocrine Biosciences' score of 0.62 indicating that Royalty Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Royalty Pharma
4 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Neurocrine Biosciences
8 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Royalty Pharma beats Neurocrine Biosciences on 9 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Zoetis?

Neurocrine Biosciences (NASDAQ:NBIX) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Zoetis has higher revenue and earnings than Neurocrine Biosciences. Zoetis is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurocrine Biosciences$2.86B5.36$478.60M$6.8222.11
Zoetis$9.47B3.30$2.67B$6.0712.46

Neurocrine Biosciences currently has a consensus price target of $200.86, indicating a potential upside of 33.18%. Zoetis has a consensus price target of $109.62, indicating a potential upside of 44.96%. Given Zoetis' higher possible upside, analysts clearly believe Zoetis is more favorable than Neurocrine Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neurocrine Biosciences
0 Sell rating(s)
4 Hold rating(s)
19 Buy rating(s)
1 Strong Buy rating(s)
2.88
Zoetis
2 Sell rating(s)
9 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.32

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Neurocrine Biosciences has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Zoetis has a net margin of 27.49% compared to Neurocrine Biosciences' net margin of 20.91%. Zoetis' return on equity of 74.89% beat Neurocrine Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Neurocrine Biosciences20.91% 22.43% 15.64%
Zoetis 27.49%74.89%18.59%

In the previous week, Zoetis had 31 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 51 mentions for Zoetis and 20 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.62 beat Zoetis' score of 0.32 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neurocrine Biosciences
8 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Positive
Zoetis
17 Very Positive mention(s)
8 Positive mention(s)
9 Neutral mention(s)
9 Negative mention(s)
2 Very Negative mention(s)
Neutral

Summary

Zoetis beats Neurocrine Biosciences on 9 of the 17 factors compared between the two stocks.

Get Neurocrine Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NBIX vs. The Competition

Export
MetricNeurocrine BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$15.91B$11.88B$7.07B$13.00B
Dividend YieldN/A2.70%2.58%10.72%
P/E Ratio22.11783.89269.6325.21
Price / Sales5.36746.05596.7299.91
Price / Cash31.2267.4570.5350.75
Price / Book4.1510.6213.116.24
Net Income$478.60M$2.77B$3.45B$347.70M
7 Day Performance-7.70%-0.10%0.78%0.87%
1 Month Performance-12.33%0.07%1.45%0.90%
1 Year Performance14.86%161.19%67.07%20.13%

Neurocrine Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NBIX
Neurocrine Biosciences
4.9864 of 5 stars		$150.82
-3.6%		$200.86
+33.2%		+14.6%$15.91B$2.86B22.112,000
TAK
Takeda Pharmaceutical
2.1353 of 5 stars		$16.85
-1.4%		N/A+17.9%$54.76B$28.32B49.5447,000
TEVA
Teva Pharmaceutical Industries
4.1274 of 5 stars		$34.39
-1.8%		$42.00
+22.1%		+112.2%$40.25B$17.26B57.3233,950
ONC
BeOne Medicines
4.3627 of 5 stars		$313.77
-0.7%		$394.00
+25.6%		+15.8%$34.67B$5.34B70.1912,000
RPRX
Royalty Pharma
4.3808 of 5 stars		$57.17
-2.2%		$56.57
-1.0%		+60.6%$33.65B$2.38B38.8980

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NBIX) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
How the JPMorgan $8,000 Gold Call Exposed the Biggest Mistake in Most Retirement Accounts
JPMorgan has raised its 2026 gold forecast to $6,300, with a credible path to $8,000, and now calls gold a cor...
Golden Crest Metals | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
American retirees will miss THIS. Big Banks just moved in.
Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...
Cedar Gold Group | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel